Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3779 177Lu-DOTATATE in advanced neuroendocrine neoplasms of different locations – Data from 552 cases in the SEPTRALU registry

Introduction: Peptide receptor radionuclide therapy (PRRT) is a therapeutic strategy selected via a marker, somatostatin receptor (SSTRs) expression, with activity in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). Its role in tumor sites outside the digestive tract remains unclear.

Conference:

Presenting Author:

Authors: Mitjavila Casanovas M, Carmona-Bayonas A, Bello P, de Matias Leralta J, Garcia Burillo A,

Keywords: 177Lu-DOTATATE, lung, neuroendocrine tumor, PRRT, pheochromocytoma, radionuclide therapy,

#2900 Radionuclide Therapy in the Continuum of Care of Neuroendocrine Tumors: Results of the SEPTRALU Study

Introduction: Peptide receptor radionuclide therapy (PRRT, Lu-177-DOTATATE) is safe and effective in neuroendocrine tumors (NET). However, the best sequence of administration is unknown.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Mitjavila Casanovas M, Carmona-Bayonas A, Pubul V, García-Cañamaque L, Aller J,

Keywords: Lu-177-DOTATATE, radionuclide, survival, treatment,

#2888 Progression-Free Survival as a Surrogate Endpoint in Gastroenteropancreatic Neuroendocrine Tumors Treated with Somatostatin Analogues

Introduction: Progression-free survival (PFS) has been used as surrogate endpoint in phase III trials with somatostatin analogues for gastroentero-pancreatic neuroendocrine tumors (GEP-NET). However, this endpoint has not been validated in this scenario.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Jimenez Fonseca P

Authors: Jimenez-Fonseca P, Carmona-Bayonas A, Lamarca A, Barriuso J, Castaño A,

Keywords: somatostatin analogues, surrogate, PFS, OS, correlation, kendall,

#2883 Comparison of Somatostatin Analogues in Metastatic Gastroenteropancreatic Neuroendocrine Tumors from a Bayesian Perspective: The GETNE-TRASGU Study

Introduction: Somatostatin analogues (SSA), octreotide LAR (Oct) and lanreotide autogel (Lan), significantly prolong progression-free survival (PFS) in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NET). However, comparative data are not available and randomized trials comparing both SSAs are unlikely to be conducted.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Carmona-Bayonas A, Jimenez-Fonseca P, Lamarca A, Barriuso J, Castaño A,

Keywords: Bayesian model, octreotide, lanreotide, progression-free survival, efficacy,

#2880 177-Lu-DOTATATE in 200 Patients with Neuroendocrine Tumors: Real-World Data from the SEPTRALU Registry

Introduction: Patients with neuroendocrine tumors have few treatment options after progression to first-line somatostatin analogues.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Carmona Bayonas A

Authors: Carmona-Bayonas A, Mitjavila Casanovas M, Belló P, Percovich J, Prieto A,

Keywords: PRRT, 177Lu-DOTATATE, radionuclide,